Novartis gets Egyptian Drug Authority approval for Kisqali early breast cancer use
Novartis said it received approval from Egypt’s Egyptian Drug Authority for Kisqali as an adjuvant treatment in early-stage breast cancer for adult patients with HR-positive, HER2-negative stage II disease.